Osteoporosis International

, Volume 23, Issue 4, pp 1361–1369

Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial

Authors

    • Cedars-Sinai/UCLA and OMC Clinical Research Center
  • H. N. Viswanathan
    • Amgen Inc
  • Y.-C. Yang
    • Amgen Inc
  • A. Wang
    • Amgen Inc
  • S. Boonen
    • Leuven University
  • S. Ragi-Eis
    • CEDOES Diagnóstico e Pesquisa
  • P. Fardellone
    • CHU Amiens, INSERM ERI 12
  • N. Gilchrist
    • CGM Research Trust and Canterbury District Health Board
  • P. Lips
    • VU University Medical Center
  • M. Nevitt
    • University of California San Francisco
  • S. Palacios Gil-Antuñano
    • Palacios Institute of Woman’s Health
  • K. Pavelka
    • Charles University
  • D. Revicki
    • United BioSource Corporation
  • J. Simon
    • Women’s Health & Research Consultants®
  • D. Macarios
    • Amgen Inc
  • E. S. Siris
    • Columbia University Medical Center
Original Article

DOI: 10.1007/s00198-011-1720-0

Cite this article as:
Silverman, S., Viswanathan, H.N., Yang, Y. et al. Osteoporos Int (2012) 23: 1361. doi:10.1007/s00198-011-1720-0

Abstract

Summary

In the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) study, women with incident clinical fractures reported significant declines in health-related quality of life (HRQoL). The largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain.

Introduction

In the FREEDOM trial, denosumab significantly reduced the risk of new vertebral, hip, and nonvertebral fractures. We evaluated the effect of denosumab on HRQoL and the association between incident clinical fractures and HRQoL.

Methods

The FREEDOM trial enrolled 7,868 women aged 60–90 years with a total hip and/or lumbar spine BMD T-score <−2.5 and not <−4.0 at either site. Women were randomized to receive denosumab 60 mg or placebo every 6 months, in addition to daily calcium and vitamin D. HRQoL was assessed with the Osteoporosis Assessment Questionnaire-Short Version (OPAQ-SV) at baseline and every 6 months for 36 months. The OPAQ-SV assesses physical function, emotional status, and back pain. Higher scores indicate better health status.

Results

No statistically significant differences in mean change in HRQoL from baseline to end of study were found when comparing treatment groups. Compared with women without any incident fractures during the study, women with incident clinical fractures reported significant declines in physical function (−4.0 vs. −0.5) and emotional status (−5.0 vs. −0.8) at month 36 (P < 0.001 for both). Importantly, time-dependent covariate analyses demonstrated that the largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain.

Conclusions

These findings not only demonstrate that incident clinical fractures impact HRQoL but also contribute new information regarding the impact of these fracture events on HRQoL over time.

Keywords

Health-related quality of lifeIncident clinical fractureOPAQ-SVOsteoporosis

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011